Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 6/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044500 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL732930 | 0.98 | ALDH1A1 (0.47) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL2045176 | 0.85 | ALDH1A1 (0.51) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL2047122 | 0.85 | ALDH1A1 (0.51) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL15623787 | 0.85 | FAAH (0.42) | ALDH1A1FAAHMEN1KMT2ANOD1 | |
| SCHEMBL731077 | 0.84 | ALDH1A1 (0.49) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL27734590 | 0.84 | ALDH1A1 (0.49) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL6562409 | 0.81 | FAAH (0.66) | ALDH1A1ABCC4MAPTLMNAFAAH | |
| SCHEMBL8515118 | 0.81 | FAAH (0.58) | ALDH1A1FAAHSLC6A5MEN1KMT2A | |
| SCHEMBL15680129 | 0.80 | PLA2G2C (0.42) | ALDH1A1LMNAFAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ALDH1A1 623/4885ABCC4 792/4885MAPT 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.